Why has PFAS litigation been slower to develop in the EU than the US? What is now driving its increase, and how can the risks be mitigated? Litigation in the US is intensifying, while in Europe it has lagged significantly behind. Yet there have been several notable cases, including actions against 3M in Belgium, Chemours in the Netherlands and Arkema in France. Nonetheless, the number of cases in Europe so far pales in comparison to those in the US.
This is “just the start”, NGO ChemSec says in a recent report, with many more cases likely to come as public awareness of the issue increases. The adoption of a universal restriction proposal on PFAS could also be a significant trigger for new litigation in Europe, but can it ever match the sheer scale of cases seen in the US?
Read more here.
